Temodar and Mekinist drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Temodar (temozolomide) and Mekinist (trametinib dimethyl sulfoxide). Common drug interactions include dry skin among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Temodar and Mekinist. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Temodar?

Temodar has active ingredients of temozolomide. It is often used in glioblastoma multiforme. eHealthMe is studying from 6,683 Temodar users. Check the latest studies of Temodar.

What is Mekinist?

Mekinist has active ingredients of trametinib dimethyl sulfoxide. eHealthMe is studying from 17,350 Mekinist users. Check the latest studies of Mekinist.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 20, 2026

12 people who take Temodar and Mekinist together, and have interactions are studied.

What are the common drug interactions of Temodar and Mekinist, by gender? *:

female:

Dry skin
Hallucination (an experience involving the perception of something not present)
Malignant neoplasm progression (cancer tumour came back)
Pain of skin
Peripheral swelling
Pruritus (severe itching of the skin)
Rash generalised (rash on most of body parts)
Secretion discharge
Brain neoplasm (tumour of brain)
Headache (pain in head)

male:

Death
Aphasia (damage to the parts of the brain that control language)
Confusional state
Dysarthria (speech disorder)
Malignant melanoma (skin cancer rises from melancytes)
Malignant neoplasm progression (cancer tumour came back)
Neoplasm malignant (cancer tumour)
Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
Oedema peripheral (superficial swelling)

What are the common drug interactions of Temodar and Mekinist, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Brain neoplasm (tumour of brain)
Headache (pain in head)
Malignant neoplasm progression (cancer tumour came back)
Tumour haemorrhage (bleeding from tumour)

20-29:

n/a

30-39:

n/a

40-49:

Confusional state
Dysarthria (speech disorder)
Malignant melanoma (skin cancer rises from melancytes)
Malignant neoplasm progression (cancer tumour came back)
Neoplasm malignant (cancer tumour)
Aphasia (damage to the parts of the brain that control language)

50-59:

n/a

60+:

Death
Dry skin
Hallucination (an experience involving the perception of something not present)
Pain of skin
Peripheral swelling
Pruritus (severe itching of the skin)
Rash generalised (rash on most of body parts)
Secretion discharge
Hospitalisation

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 6 people, 50.00%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 2 people, 16.67%
Brain Neoplasm Malignant (brain cancer tumour): 2 people, 16.67%
Pain: 1 person, 8.33%
Neoplasm Malignant (cancer tumour): 1 person, 8.33%
Nausea And Vomiting: 1 person, 8.33%
Itching: 1 person, 8.33%
Diarrhea: 1 person, 8.33%
Constipation: 1 person, 8.33%
Brain Neoplasm (tumour of brain): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Temodar and Mekinist?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously